Herzliya, Israel — December 4, 2025 — Leads & Copy — Regentis Biomaterials Ltd. (NYSE American: RGNT) has announced the pricing of its initial public offering of 1,250,000 ordinary shares at $8.00 per share, resulting in gross proceeds of $10 million, before deducting underwriting discounts and offering expenses.
The company has granted underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares to cover over-allotments.
The ordinary shares are expected to begin trading on the NYSE American LLC on December 4, 2025, under the ticker symbol “RGNT”. The offering is expected to close around December 5, 2025, pending customary closing conditions.
Regentis plans to use the net proceeds from the offering primarily for development activities, including the completion of its pivotal trial, preparation of the PMA submission for GerlinC, repayment of certain debt and deferred compensation payments, and other corporate purposes.
ThinkEquity is the sole book-running manager for the offering.
The company has filed a registration statement on Form F-1 (File No. 333-285692) with the SEC, which became effective on November 12, 2025. The offering is being made only by means of a prospectus, available from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The preliminary prospectus has been filed with the SEC and is available on the SEC’s website.
Regentis Biomaterials Ltd. focuses on orthopedic treatments using its Gelrin platform, which are based on degradable hydrogel implants designed to regenerate damaged or diseased tissue. Its lead product candidate, GelrinC, a cell-free, off-the-shelf hydrogel, is intended as a temporary implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC has already been approved as a device with a Conformité Européene mark in Europe. The company plans to commercialize the product in Europe, while also focusing on completing its pivotal study for FDA approval.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
Forward-looking statements in this release are based on current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. The company undertakes no duty to update such information except as required under applicable law.
For Investor Relations Inquiries:
Arie Gordashnikov
arie@shimony.com
+972-3-6116629
Source: Regentis Biomaterials Ltd.
